Targets › F13A1
1 program from 1 company in 1 trial: 1 Phase 4; Hematology; next expected readout Jun 2028.
Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. (UniProt, P00488)
Open in Phaseline: the race on F13A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Christian Haslinger | Fibrogammin (DRUG) Coagulation factor XIII (FXIII) replacement | F13A1 | Phase 4 | Postpartum Hemorrhage | Jun 2028 |
Postpartum Hemorrhage (1)
protein or peptide (1)
Christian Haslinger (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.